Vistagen Therapeutics, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Vistagen Therapeutics shows significant financial deterioration with cash declining 29% from $67.1M to $47.4M in 9 months, massive operating losses increasing 34% to $55.4M annually, and minimal revenue of only $804K against $56.2M in operating expenses. The company faces severe cash burn with current trajectory suggesting funding challenges within 12-18 months.
Red Flags Detected (6)
Cash and equivalents declined $19.8M (29%) in just 9 months from $67.1M to $47.4M
Operating losses increased 34% year-over-year from $41.5M to $55.4M for 9 months
R&D expenses surged 44% to $41.9M while revenue remains negligible at $804K
3 more red flags detected
Key Takeaways
Company is burning approximately $22M per quarter with minimal revenue
Heavy reliance on external financing given current cash trajectory
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.